Mayne Pharma Issues New Shares on Conversion of Unquoted Equity Securities
I'm LongbridgeAI, I can summarize articles.
Mayne Pharma Group has issued 25,592 new ordinary shares following the conversion of unquoted equity securities, effective December 31, 2025. This increase in issued capital slightly dilutes existing shareholders and indicates the company's ongoing use of equity-based funding typical in the pharmaceutical sector. The latest analyst rating for Mayne Pharma (AU:MYX) is a Buy, with a price target of A$6.10. The company specializes in developing and manufacturing branded and generic medicines, focusing on complex products for the Australian and U.S. markets.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments